Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA043888-06
Application #
3186341
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1987-05-01
Project End
1993-01-31
Budget Start
1993-01-01
Budget End
1993-01-31
Support Year
6
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Yale University
Department
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Wu, Hao; Zhu, Hua; Liu, David X et al. (2009) Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. Cancer Res 69:2453-60
Hait, William N; Jin, Shengkan; Yang, Jin-Ming (2006) A matter of life or death (or both): understanding autophagy in cancer. Clin Cancer Res 12:1961-5
Hait, William N; Wu, Hao; Jin, Shenkan et al. (2006) Elongation factor-2 kinase: its role in protein synthesis and autophagy. Autophagy 2:294-6
Wu, Hao; Yang, Jin-Ming; Jin, Shengkan et al. (2006) Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res 66:3015-23
Hait, William N; Yang, Jin-Ming (2005) Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Semin Oncol 32:S16-21
Arora, Sonia; Yang, Jin-Ming; Hait, William N (2005) Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res 65:3806-10
Arora, Sonia; Yang, Jin-Ming; Utsumi, Ryutaro et al. (2004) P-glycoprotein mediates resistance to histidine kinase inhibitors. Mol Pharmacol 66:460-7
Hait, William N; Rubin, Eric; Goodin, Susan (2003) Tubulin-targeting agents. Cancer Chemother Biol Response Modif 21:41-67
Hait, William N; Rubin, Eric; Goodin, Susan (2002) Tubulin-targeting agents. Cancer Chemother Biol Response Modif 20:71-97
Sullivan, Gregory F; Garcia-Welch, Adrienne; White, Eileen et al. (2002) Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53. J Exp Ther Oncol 2:19-26

Showing the most recent 10 out of 42 publications